By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DBV Technologies 

29 rue du Faubourg

Saint Jacques  Paris  75014  France
Phone: 33-0-1-55-389270 Fax: 33-0-1-41-312882


Company News
DBV Technologies To Attend The Goldman, Sachs & Co. European Biotech Symposium 8/26/2014 7:22:48 AM
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014 10:15:00 AM
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014 6:12:23 AM
DBV Technologies To Present At Upcoming US Investors Conferences 6/17/2014 9:13:11 AM
Five Scientific Communications At The European Academy Of Allergy And Clinical Immunology Congress Further Support DBV Technologies's EPIT™ Disease Modifying Effect 6/11/2014 7:18:56 AM
DBV Technologies Announces Clinical Trial Agreement To Develop A Treatment For Milk-Induced Eosinophilic Esophagitis In Children 5/13/2014 11:54:21 AM
DBV Technologies To Host And Webcast Investor Day In New York City On May 21, 2014 5/12/2014 10:05:48 AM
DBV Technologies Announces The First Reported Case Of A Long Term Sustained Effect Of Peanut Desensitization After Epicutaneous Immunotherapy (EPIT) With Viaskin® At The French Congress Of Allergy 4/16/2014 9:51:14 AM
DBV Technologies Announces Topline Financial Results For First Three Months 2014 4/15/2014 9:37:37 AM
DBV Technologies And CEA Conclude A Scientific Cooperation To Investigate Epigenetic Modulation In Epicutaneous Immunotherapy 4/9/2014 8:49:18 AM